Boston University School of Medicine, 650 Albany St, Suite X-200, Clinical Epidemiology Unit, Boston, MA, 02118, USA,
Osteoporos Int. 2014 Jun;25(6):1677-84. doi: 10.1007/s00198-014-2662-0. Epub 2014 Mar 29.
Association between warfarin use and fracture risk is unclear. We examined the association between long-term warfarin use and fracture risk at the hip, spine, and wrist in elders. No significant association was found between long-term warfarin use and fracture risk, despite biological plausibility.
Prior studies examining the association of warfarin use and osteoporotic fractures have been conflicting, potentially related to methodological limitations. Thus, we examined the association of long-term warfarin use with risk of hip, spine, and wrist fractures among older adults with atrial fibrillation, attempting to address prior methodologic challenges.
We included men and women ≥ 65 years of age with incident atrial fibrillation and without prior history of fractures from The Health Improvement Network followed between 2000 and 2010. Long-term warfarin use was defined in two ways: (1) warfarin use ≥ 1 year; (2) warfarin use ≥ 3 years. Propensity-score matched cohorts of warfarin users and nonusers were created to evaluate the association between long-term warfarin use and risk of hip, spine, and wrist fractures separately as well as combined, using Cox-proportional hazards regression models.
Among >20,000 participants with incident atrial fibrillation, the hazard ratios (HR) for hip fracture with warfarin use ≥ 1 and ≥ 3 years, respectively, were 1.08 (95%CI 0.87, 1.35) and 1.13 (95% CI 0.84, 1.50). Similarly, no significant associations were observed between long-term warfarin use and risk of spine or wrist fracture. When risk of any fracture was assessed with warfarin use, no association was found [HR for warfarin use ≥ 1 year 0.92 (95%CI 0.77, 1.10); HR for warfarin use ≥ 3 years 1.12 (95%CI 0.88, 1.43)].
Long-term warfarin use among elders with atrial fibrillation was not associated with increased risk of osteoporotic fractures and therefore does not appear to necessitate additional surveillance or prophylaxis.
华法林使用与骨折风险之间的关系尚不清楚。我们研究了长期使用华法林与老年人髋部、脊柱和腕部骨折风险之间的关系。尽管具有生物学合理性,但未发现长期使用华法林与骨折风险之间存在显著关联。
先前研究检查了华法林使用与骨质疏松性骨折之间的关联,但结果存在冲突,这可能与方法学局限性有关。因此,我们研究了长期使用华法林与年龄较大的房颤患者髋部、脊柱和腕部骨折风险之间的关联,试图解决先前方法学上的挑战。
我们纳入了 2000 年至 2010 年间来自健康改进网络的年龄在 65 岁及以上、无骨折既往史的新发房颤患者。长期使用华法林的定义有两种:(1)华法林使用≥1 年;(2)华法林使用≥3 年。使用倾向性评分匹配的华法林使用者和非使用者队列,分别使用 Cox 比例风险回归模型评估长期使用华法林与髋部、脊柱和腕部骨折风险之间的关联,以及联合风险。
在超过 20000 名新发房颤患者中,华法林使用≥1 年和≥3 年的髋部骨折风险比(HR)分别为 1.08(95%CI 0.87,1.35)和 1.13(95%CI 0.84,1.50)。同样,长期使用华法林与脊柱或腕部骨折风险之间也没有显著关联。当使用华法林评估任何骨折风险时,未发现关联[华法林使用≥1 年的 HR 为 0.92(95%CI 0.77,1.10);华法林使用≥3 年的 HR 为 1.12(95%CI 0.88,1.43)]。
在年龄较大的房颤患者中,长期使用华法林与骨质疏松性骨折风险增加无关,因此似乎不需要额外的监测或预防。